Volume 26, Number 12—December 2020
CME ACTIVITY - Research
Tuberculosis among Children and Adolescents at HIV Treatment Centers in Sub-Saharan Africa
Table 3
Variable |
Odds ratio (95% CI) |
p value |
Country | ||
Swaziland, Lesotho, Malawi, Tanzania-Mbeya, Tanzania-Mwanza, and Uganda | Referent | |
Botswana |
0.09 (0.00–22.83) |
0.1811 |
TB drug resistance | ||
Not tested, multidrug resistance, and not detected | Referent | |
Monoresistance |
18.11 (0.00–31,381.00) |
0.4642 |
ART category | ||
On ART >6 mos before TB treatment, on ART <6 mos before TB treatment, and on ART >8 wks after TB treatment | Referent | |
Never on ART | 3.38 (0.21–20.02) | 0.2168 |
On ART <8 wks after starting TB treatment |
0.41 (0.14–0.60) |
0.0051† |
Immune status | ||
Advanced | Referent | |
Not advanced | 0.42 (0.13–0.94) | 0.0412† |
Severe |
1.88 (0.70–4.80) |
0.1233 |
Each increasing WHO stage | 3.64 (2.50–7.17) | <0.001‡ |
*Variables included were sex, COE, site of TB, TB treatment category, TB drug resistance, age at ATT initiation, days in care at COE, immune status, ART TB days, ART category, and World Health Organization stage; all elements under each variable are described in Table 2. Variables excluded were ART regimen pre-ATT initiation, and total ART drugs pre-ATT treatment. ART, antiretroviral therapy; ATT, anti-TB therapy; COE, Center of Excellence; TB, tuberculosis. †Significant result (p<0.05). ‡Significant result (p<0.01).
1These authors contributed equally to this article.
Page created: September 10, 2020
Page updated: December 01, 2020
Page reviewed: December 01, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.